The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Structural and Signaling Requirements for BCR-ABL-Mediated Transformation and Inhibition of Apoptosis
Open accessAbstract
BCR-ABL is a deregulated tyrosine kinase expressed in Philadelphia chromosome-positive human leukemias. Prolongation of hematopoietic cell survival by inhibition of apoptosis has been proposed to be an integral component of BCR-ABL-induced chronic myelogenous leukemia. BCR-ABL elicits transformation of both fibroblast and hematopoietic cells and blocks apoptosis following cytokine deprivation in various factor-dependent cells. To elucidate the mechanisms whereby BCR-ABL induces transformation and blocks apoptosis in hematopoietic cells, we examined the biological effects of expression of a series of BCR-ABL mutants. Single amino acid substitutions in the GRB2 binding site (Y177F), Src homology 2 domain (R552L), or an autophosphorylation site in the tyrosine kinase domain (Y793F) do not diminish the antiapoptotic and transforming properties of BCR-ABL in hematopoietic cells, although these mutations were previously shown to drastically reduce the transforming activity of BCR-ABL in fibroblasts. A BCR-ABL molecule containing all three mutations (Y177F/R552L/Y793F) exhibits a severe decrease in transforming and antiapoptotic activities compared with the wild-type BCR-ABL protein in 32D myeloid progenitor cells. Ras is activated, the SHC adapter protein is tyrosine phosphorylated and binds GRB2, and myc mRNA levels are increased following expression of all kinase active BCR-ABL proteins with the exception of the Y177F/R552L/Y793F BCR-ABL mutant in 32D cells. We propose that BCR-ABL uses multiple pathways to activate Ras in hematopoietic cells and that this activation is necessary for the transforming and antiapoptotic activities of BCR-ABL. However, Ras activation is not sufficient for BCR-ABL-mediated transformation. A BCR-ABL deletion mutant (delta 176-427) that activates Ras and blocks apoptosis but has severely impaired transforming ability in 32D cells has been identified. These data suggest that BCR-ABL requires additional signaling components to elicit tumorigenic growth which are distinct from those required to block apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
Protein modules and signalling networks
Pawson, T. (1995) · Nature · doi:10.1038/373573a0 · Cited by 2,420
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
Mechanisms and Functions of Cell Death
Ellis, R. E., Yuan, J., & Horvitz, H. R. (1991) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.07.110191.003311 · Cited by 2,057
Features of apoptotic cells measured by flow cytometry
Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M. A., Lassota, P., & Traganos, F. (1992) · Cytometry · doi:10.1002/cyto.990130802 · Cited by 1,883
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Grignani, F., Pawson, T., & Giuseppe Pelicci, P. (1992) · Cell · doi:10.1016/0092-8674(92)90536-l · Cited by 1,326
Apoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1
Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., & Bowtell, D. (1993) · Nature · doi:10.1038/363083a0 · Cited by 1,009
p53-Dependent apoptosis suppresses tumor growth and progression in vivo
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., & Van Dyke, T. (1994) · Cell · doi:10.1016/0092-8674(94)90534-7 · Cited by 880 · cited 1×
“Deregulation of apoptosis is important in the initiation and progression of many cancers (15, 21, 53, 56).”
Background
Cited by
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Self-citationThe biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35660 · Cited by 570
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567
“The expression of cytoplasmic BCR/ABL proteins (Dhut et al., 1990) is associated with the activation of several downstream effector molecules (Cortez et al., 1995).”
BackgroundResultInfluentialThe BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
A requirement for NF-kappa B activation in Bcr-Abl-mediated transformation
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., & Baldwin Jr., A. S. (1998) · Genes & Development · doi:10.1101/gad.12.7.968 · Cited by 392
Self-citationCritical role for Gab2 in transformation by BCR/ABL
Sattler, M., Mohi, M. G., Pride, Y. B., Quinnan, L. R., Malouf, N. A., Podar, K., Gesbert, F., Iwasaki, H., Li, S., Van Etten, R. A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00074-0 · Cited by 364
Vigneri, P., & Wang, J. Y. J. (2001) · Nature Medicine · doi:10.1038/84683 · Cited by 331
Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.1997.0155 · Cited by 316
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Bai, R.-Y., Dieter, P., Peschel, C., Morris, S. W., & Duyster, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.6951 · Cited by 281
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., & Skorski, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1229 · Cited by 271
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP- binding protein Rac
Skorski, T., Wlodarski, P., Daheron, L., Salomoni, P., Nieborowska-Skorska, M., Majewski, M., Wasik, M., & Calabretta, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11858 · Cited by 89
Zhao, R. C. H., McIvor, R. S., Griffin, J. D., & Verfaillie, C. M. (1997) · Blood · doi:10.1182/blood.v90.12.4687 · Cited by 48
Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway
Bassermann, F., Jahn, T., Miething, C., Seipel, P., Bai, R.-Y., Coutinho, S., Peschel, C., Duyster, J., & Tybulewicz, V. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112397200 · Cited by 47
Metadata
- Authors
- Cortez, D., Kadlec, L., & Pendergast, A. M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1995-10
- Volume
- 15
- Issue
- 10
- Pages
- 5531-5541
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2142618806
- Cited by
- 267
- References
- 53
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.